Recurrent Head and Neck Cancer
1 competing product in clinical development for Recurrent Head and Neck Cancer.
Pipeline by Phase
Phase 21
All Products (1)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Ramucirumab + Pembrolizumab | Eli Lilly | Phase 2 | Active | 52 |
1 competing product in clinical development for Recurrent Head and Neck Cancer.
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| Ramucirumab + Pembrolizumab | Eli Lilly | Phase 2 | Active | 52 |